Antheia Wins $80M Conditional OSC Loan to Onshore Drug Supply
Menlo Park, Calif. – October 18, 2026 -- Antheia has received a conditional commitment from the U.S. Department of War's Office of Strategic Capital (OSC) for a direct, long-term loan of up to $80 million to expand domestic production of critical pharmaceutical ingredients.
The loan, together with additional private capital, would fund Antheia's U.S. manufacturing strategy. The company's advanced biosynthesis platform is the technology behind the planned onshoring effort.
U.S. depends on foreign suppliers for about 90 percent of key drug inputs
The U.S. relies on foreign countries for approximately 90 percent of its key starting materials (KSMs) and active pharmaceutical ingredients (APIs). The source names public health emergencies, natural disasters, geopolitical tensions and supply chain failures as drivers of drug shortages that follow from this dependence.